FIB-4 vs NASH/FibroSure: Key Differences for Hepatic Steatosis Assessment
FIB-4 is a simple, free calculator using age and routine lab values (AST, ALT, platelets) that assesses fibrosis stage, while FibroSure (also called FibroTest) is a proprietary blood test measuring specific serum biomarkers that also stages fibrosis—neither test directly measures hepatic steatosis itself.
What Each Test Actually Measures
FIB-4 Index
- Purpose: Stages liver fibrosis (scarring), NOT steatosis (fat accumulation)
- Components: Age, AST, ALT, platelet count
- Cost: Free calculation
- Validated cutoffs: <1.45 rules out advanced fibrosis (F3-F4) with 94.7% negative predictive value; >3.25 confirms advanced fibrosis with 82.1% positive predictive value 1
- Performance: Correctly classifies 72.8% of patients when using these thresholds 1
FibroSure/FibroTest
- Purpose: Also stages liver fibrosis, NOT steatosis
- Components: Proprietary panel of serum biomarkers (specific proteins involved in fibrosis)
- Cost: Commercial test requiring payment
- Concordance with FIB-4: When FIB-4 values are <1.45 or >3.25, FibroSure agrees 92.1% and 76% of the time, respectively 1
Critical Distinction: Neither Test Measures Steatosis
Both tests assess fibrosis stage, which is the amount of liver scarring and proximity to cirrhosis—not the degree of fat accumulation (steatosis). 2 For steatosis assessment, you need different tools:
- Controlled Attenuation Parameter (CAP) on FibroScan identifies advanced steatosis in 89.7% of biopsy-confirmed cases 3
- NAFLD Liver Fat Score (NLFS) has only 58-61% accuracy for steatosis 4
Guideline-Recommended Approach
FIB-4 is recommended as the first-line assessment tool over FibroSure based on its simplicity and zero cost, despite FibroSure having comparable accuracy. 2 The 2023 AGA guidelines explicitly state that while FIB-4 does not outperform proprietary biomarkers like FibroSure, it is preferred for initial risk stratification 2.
Sequential Testing Algorithm (Per 2023 AGA Guidelines)
- Calculate FIB-4 first in all patients with NAFLD/MASLD
- If FIB-4 <1.45: Low risk, reassess in 2-3 years
- If FIB-4 1.45-3.25: Indeterminate zone—proceed to elastography (FibroScan) or consider FibroSure if elastography unavailable 2
- If FIB-4 >3.25: High risk, refer to hepatology
Performance Comparison in Real-World Practice
The 2025 AASLD systematic review found both tests provide "small-to-moderate change in pretest probability" for diagnosing advanced fibrosis 5. Key limitations:
- FIB-4 feasibility issue: In real-world diabetes clinics, only 36% of patients had complete lab data needed to calculate FIB-4 (AST/ALT frequently missing) 6
- Both tests have significant false rates: When compared to liver biopsy, false positive rates of 36-39% and false negative rates of 15-18% for advanced fibrosis 7
- FibroScan combined with FIB-4 achieves only 68.9% concordance with liver biopsy even when using society-recommended thresholds 3
Common Pitfalls to Avoid
- Don't use either test to diagnose steatosis—they measure fibrosis only
- Don't skip FIB-4 and go straight to FibroSure—guidelines prioritize the free test first 2
- Don't trust a single test in the indeterminate zone (FIB-4 1.45-3.25)—this requires additional testing with elastography or alternative biomarkers
- Don't assume normal FIB-4 means no disease—it only rules out advanced fibrosis, not early-stage disease or steatosis
When to Consider FibroSure Over FIB-4
FibroSure may be appropriate as a secondary assessment when:
- Elastography is unavailable 2
- FIB-4 falls in the indeterminate range (1.45-3.25)
- Routine liver enzymes are not available for FIB-4 calculation
The bottom line: Use FIB-4 first for fibrosis risk stratification due to cost and accessibility, reserving FibroSure for situations where elastography is unavailable and FIB-4 is indeterminate. For actual steatosis assessment, you need imaging-based tools like CAP on FibroScan, not either of these blood tests.